Essex Investment Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Essex Investment Management’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40,828	Closed	-$190K	–	516
2020 Q2	$190K	Sell	40,828 -24,600	-38%	-$127K	0.03%	315
2020 Q1	$339K	Sell	65,428 -1,515	-2%	-$11K	0.07%	248
2019 Q4	$335K	Buy	66,943 +2,366	+4%	+$15.3K	0.04%	345
2019 Q3	$513K	Hold	64,577	–	–	0.07%	288
2019 Q2	$468K	Buy	64,577 +27,416	+74%	+$201K	0.06%	308
2019 Q1	$297K	Buy	37,161 +3,193	+9%	+$30K	0.04%	308
2018 Q4	$272K	Buy	33,968 +3,751	+12%	+$45K	0.04%	301
2018 Q3	$465K	Buy	+30,217	New	+$364K	0.05%	302

Other funds holding IDXG

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Essex Investment Management's IDXG Position: Q3 2020 in Review

Essex Investment Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2020, closing a stake of 40,828 shares — an estimated $190K sold.

Essex Investment Management first reported a position in IDXG in Q3 2018 and held it in 8 quarters. The position peaked at $513K in Q3 2019. 18 funds tracked by Wall St. Rank hold IDXG as of Q3 2020.

Essex Investment Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Essex Investment Management sold 40,828 Interpace Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $190K.
Essex Investment Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2018 and held it in 8 quarters.
Essex Investment Management's Interpace Biosciences, Inc. Common Stock position peaked at $513K in Q3 2019.
18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2020.

Based on Essex Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.